Abstract
Dendritic cells (DCs) are potent antigen-presenting cells that prime naive cytotoxic T-cells (CTLs)1. In this study, we have fused DCs with MC38 carcinoma cells. The fusion cells were positive for major histocompatibility (MHC) class I and II, costimulating molecules and intercellular cell adhesion molecule-1 (ICAM-1). The results show that the fusion cells stimulate naive T cells in the primary mixed lymphocyte reaction (MLR) and induce MC38 tumor-specific CTLs in vivo. Antibody-mediated depletion experiments demonstrate that induction of CD4+ and CD8+ CTLs protects against challenge with tumor cells. We also show that immunization with the fusion cells induces rejection of established metastases. These findings represent the first demonstration that fusions of DCs and tumor cells can be used in the treatment of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Steinman, R.M. The dendritic Cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
Young, J.W. & Inaba, K., Dendritic Cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183, 7–11 (1996).
Siddiqui, J. et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA 85, 2320–2323 (1988).
Steinman, R.M. & Witmer, M.D. Lymphoid dendritic Cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc. Natl. Acad. Sci. USA 75, 5132–5136 (1978).
Van Voorhis, W.C. et al. Relative efficacy of human monocytes and dendritic Cells as accessory Cells for T Cell replication. J. Exp. Med. 158, 174–191 (1983).
Inaba, K., Young, J.W. & Steinman, R.M. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic Cells. J. Exp. Med. 166, 182–194 (1987).
Young, J.W. & Steinman, R.M. Dentritic Cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T Cells. J. Exp. Med. 171, 1315–1332 (1990).
Inaba, K., Metlay, J.P., Crowley, M.T. & Steinman, R.M., Dendritic Cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T Cells in situ. J. Exp. Med. 172, 631–640 (1990).
Liu, L.M. & MacPherson, G.G. Antigen acquisition by dendritic Cells: Intestinal dendritic Cells acquire antigen administered orally and can prime naive T Cells in vivo. J. Exp. Med. 177, 1299–1307 (1993).
Macatonia, S.E., Taylor, P.M., Knight, S.C. & Askonas, B.A. Primary stimulation by dendritic Cells induces antiviral proliferative and cytotoxic T Cell responses in vitro. J. Exp. Med. 169, 1255–1264 (1988).
Mehta-Damani, A., Markowicz, S. & Engleman, E.G. Generation of antigen-specific CD8+ CTLs from naive precursors. J. Immunol. 153, 996–1003 (1994).
Takahashi, H., Nakagawa, Y., Yokomuro, K. & Berzofsky, J.A. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic Cells. Int. Immunol. 5, 849–857 (1993).
Mayordomo, J.I. et al. Bone marrow-derived dendritic Cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297–1302 (1995).
Bakkar, A.B.H. et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic Cells in vitro. Cancer Res. 55, 5330–5334 (1995).
Flamand, V. et al. Murine dendritic Cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605–610 (1994).
Guo, Y. et al. Effective tumor vaccine generated by fusion of hepatoma Cells with activated B Cells. Science 263, 518–520 (1994).
Romani, N. et al. Proliferating dendritic Cell progenitors in human blood. J. Exp. Med. 180, 83–93 (1994).
Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic Cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109–1118 (1994).
Porgador, A. & Gilboa, E. Bone marrow-generated dendritic Cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182, 255–260 (1995).
Inaba, K. et al. Generation of large numbers of dendritic Cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693–1702 (1992).
Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36, 641–643 (1966).
Akagi, J. et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-Cell costimulatory molecule B7. J. Immunother. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gong, J., Chen, D., Kashiwaba, M. et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3, 558–561 (1997). https://doi.org/10.1038/nm0597-558
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0597-558
This article is cited by
-
In vitro and in vivo detection of tunneling nanotubes in normal and pathological osteoclastogenesis involving osteoclast fusion
Laboratory Investigation (2021)
-
Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells
Nature Communications (2019)
-
Myoblast fusion confusion: the resolution begins
Skeletal Muscle (2018)
-
Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity
Scientific Reports (2017)
-
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines
Pediatric Research (2016)